Related Experiment Video
Updated: Sep 26, 2025

RhoC GTPase Activation Assay
Published on: August 22, 2010
The Role of Fast-Cycling Atypical RHO GTPases in Cancer
1Rudbeck Laboratory, Department of Immunology, Genetics and Pathology (IGP), Uppsala University, SE-751 85 Uppsala, Sweden.
Abstract:
The RHO GTPases comprise a subfamily within the RAS superfamily of small GTP-hydrolyzing enzymes and have primarily been ascribed roles in regulation of cytoskeletal dynamics in eukaryotic cells. An oncogenic role for the RHO GTPases has been disregarded, as no activating point mutations were found for genes encoding RHO GTPases. Instead, dysregulated expression of RHO GTPases and their regulators have been identified in cancer, often in the context of increased tumor cell migration and invasion. In the new landscape of cancer genomics, activating point mutations in members of the RHO GTPases have been identified, in particular in RAC1, RHOA, and CDC42, which has suggested that RHO GTPases can indeed serve as oncogenes in certain cancer types. This review describes the current knowledge of these cancer-associated mutant RHO GTPases, with a focus on how their altered kinetics can contribute to cancer progression.
Insights
RHO GTPases, once overlooked as oncogenes, are now recognized for their role in cancer. Activating mutations in RAC1, RHOA, and CDC42 drive tumor progression by altering cell dynamics.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- RHO GTPases regulate cytoskeletal dynamics in eukaryotic cells.
- Previously, oncogenic roles were disregarded due to a lack of activating mutations.
- Dysregulated expression is linked to cancer cell migration and invasion.
Purpose of the Study:
- To review current knowledge on cancer-associated mutant RHO GTPases.
- To focus on how altered kinetics of mutant RHO GTPases contribute to cancer progression.
Main Methods:
- Literature review of cancer genomics and RHO GTPase research.
- Analysis of identified activating point mutations in RAC1, RHOA, and CDC42.
- Focus on the functional consequences of altered RHO GTPase kinetics.
Main Results:
- Activating point mutations in RAC1, RHOA, and CDC42 have been identified in cancer genomics.
- These mutations suggest RHO GTPases can function as oncogenes.
- Altered kinetics of mutant RHO GTPases are implicated in cancer progression.
Conclusions:
- RHO GTPases, particularly RAC1, RHOA, and CDC42, can act as oncogenes.
- Understanding mutant RHO GTPase kinetics is crucial for cancer research.
- This review highlights the evolving role of RHO GTPases in oncogenesis.
More Related Videos
10:27Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
Published on: March 9, 2012
13:51Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
Cell Polarization by Rho Proteins
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
GTPases and their Regulation
Large G-proteins,...
Rab Cascades